These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38346789)

  • 1. Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.
    Yang W; Wu H; Cai X; Lin C; Luo Y; Hu S; Li Z; Jiao R; Bai S; Liu G; Yang X; Ji L
    Obes Rev; 2024 Jun; 25(6):e13725. PubMed ID: 38346789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
    Zeng Q; Xu J; Mu X; Shi Y; Fan H; Li S
    Front Endocrinol (Lausanne); 2023; 14():1214334. PubMed ID: 37908750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li W; Xu L; Zhang H; Li Y
    BMJ; 2022 Jun; 377():e068882. PubMed ID: 35764326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
    Yu M; Yang Z; Chen C; Lv Y; Xiang L; Zhao S; Li R
    Diabetol Metab Syndr; 2022 Oct; 14(1):153. PubMed ID: 36271423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen therapy on gallbladder disease.
    Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
    JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study of the Conservative Management of Asymptomatic Preoperative and Postoperative Gallbladder Disease in Bariatric Surgery.
    Pineda O; Maydón HG; Amado M; Sepúlveda EM; Guilbert L; Espinosa O; Zerrweck C
    Obes Surg; 2017 Jan; 27(1):148-153. PubMed ID: 27324135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity.
    Capristo E; Maione A; Lucisano G; Russo MF; Mingrone G; Nicolucci A
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2587-2595. PubMed ID: 34154892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials.
    Stokes CS; Gluud LL; Casper M; Lammert F
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1090-1100.e2; quiz e61. PubMed ID: 24321208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    LeBlanc ES; Patnode CD; Webber EM; Redmond N; Rushkin M; O'Connor EA
    JAMA; 2018 Sep; 320(11):1172-1191. PubMed ID: 30326501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of management of gallbladder disease in patients undergoing minimally invasive bariatric surgery.
    Leyva-Alvizo A; Arredondo-Saldaña G; Leal-Isla-Flores V; Romanelli J; Sudan R; Gibbs KE; Petrick A; Soriano IS;
    Surg Obes Relat Dis; 2020 Jan; 16(1):158-164. PubMed ID: 31839526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallstones, gallbladder disease, and pancreatitis: cross-sectional and 2-year data from the Swedish Obese Subjects (SOS) and SOS reference studies.
    Torgerson JS; Lindroos AK; Näslund I; Peltonen M
    Am J Gastroenterol; 2003 May; 98(5):1032-41. PubMed ID: 12809825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
    Nauck MA; Muus Ghorbani ML; Kreiner E; Saevereid HA; Buse JB;
    Diabetes Care; 2019 Oct; 42(10):1912-1920. PubMed ID: 31399438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
    Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.